Clinical trials: Apatinib
Advanced Esophagus Cancer
Apatinib Treatment for Advanced Esophagus Cancer
Subject ever received a standard chemotherapy solution progression or recurrence or can't tolerate chemotherapy with advanced esophageal squamous carcinoma.
- Trial name
- NCT03170310
- Testing
- Apatinib
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Henan Cancer Hospital
Metastatic Gastric Cancer
An Open Label, Prospective, Multicentre, Non-interventional Study of Apatinib for Chemotherapy-Refractory Advanced Metastatic Gastric Cancer
This is an Open Label, Prospective, Multicentre, Non-interventional Study of Apatinib for Chemotherapy-Refractory Advanced Metastatic Gastric Cancer, the investigators opted to give patients for apatinib 850 mg once daily, 28…
- Trial name
- AHEAD-G202 (NCT02668380)
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Peking Union Medical College Hospital
Soft Tissue Sarcoma
Apatinib Mesylate Combined With Doxorubicin and Ifosfamide in Advanced Soft-tissue Sarcoma
Apatinib mesylate is a multitarget receptor tyrosine kinase inhibitor. This trial is to evaluate the efficacy and safety of apatinib mesylate combined with doxorubicin and ifosfamide in the treatment of advanced soft tissue…
- Trial name
- NCT04012827
- Testing
- Apatinib Mesylate, doxorubicin, ifosfamide
- Where
- China
- Volunteers
- 108 people
- Sponsor
- Sun Yat-sen University
Malignant Melanoma
Clinical Study of Apatinib as the Second-line Therapy in Malignant Melanoma
The purpose of this study is to confirm the safety and efficacy of Apatinib as the Second-line Therapy in Malignant Melanoma.
- Trial name
- NCT03383237
- Testing
- Apatinib
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Henan Cancer Hospital
Gastric Cancer
Apatinib as Maintenance Therapy After Adjuvant Chemotherapy in Progressive Gastric Cancer With Positive Exfoliative Cancer Cells
The purpose of this study is to assess the efficacy and safety of apatinib as maintenance therapy after adjuvant chemotherapy in progressive gastric cancer patients with positive exfoliative cancer cells.
- Trial name
- NCT02510469
- Testing
- Apatinib
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Hebei Medical University
Lung Squamous Cell Carcinoma
Apatinib for Advanced Lung Squmamous Carcinoma
In order to search for effective and low toxicity anti-tumor angiogenesis drugs, jiangsu hengrui pharmaceutical co., ltd. developed the high-efficiency VEGFR2 tyrosine kinase inhibitor apatinib.
- Trial name
- NCT03725423
- Testing
- Apatinib
- Volunteers
- 50 people
- Sponsor
- Xuzhou Central Hospital
Non-small Cell Lung Cancer
Application of Pablizumab Combined With Apatinib and Chemotherapy in Resectable Non-small Cell Lung Cancer： A Prospective, Single Arm, Single Center Phase II Clinical Study of Neoadjuvant Therapy
This is a prospective, single arm, single center clinical study to determine the efficacy and safety of pablizumab combined with apatinib and neoadjuvant chemotherapy in patients with stage iia-iiia non-small cell lung cancer.
- Trial name
- NCT04968002
- Testing
- pablizumab combined with apatinib and neoadjuvant chemotherapy
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Breast Cancer
Clinical Study of Apatinib Combined With SBRT Therapy in the Treatment of Oligometastasis of Breast Cancer
The treatment of the patients with metastatic breast cancer remains a major problem. However, there is an intermediate state between the primary tumor and distant metastases called oligometastasis.
- Trial name
- NCT03457467
- Testing
- Apatinib, SBRT
- Volunteers
- 30 people
- Sponsor
- Yan Li
Esophageal Squamous Cell Carcinoma, Apatinib
Apatinib in the Treatment of Recurrence or Metastasis of Esophageal Cancer
It was difficult to obtain clinical benefits through traditional chemotherapy and radiotherapy for the patients who have recurrence or metastasis tumor even though they have received first-line chemotherapy or combined…
- Conditions
- Esophageal Squamous Cell Carcinoma, Apatinib, Recurrence, Metastasis
- Trial name
- NCT03913182
- Testing
- apatinib
- Where
- China
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Shanghai Chest Hospital
Gastric Cancer
The Study of Conversion Surgery for Apatinib in Combination With SOX for Patients With Unresectable Gastric Cancer
This is a Prospective，Single-center，Single-arm，Open-label exploratory clinical trial evaluating the efficacy and safety of Conversion Surgery for Apatinib plus SOX for patients with unresectable gastric cancer.
- Trial name
- NCT03007446
- Testing
- Apatinib, Oxaliplatin, S-1
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Chinese PLA General Hospital
Biliary Tract Malignancies
A Study of Adebrelimab in Combination With Apatinib Gemcitabine and Cisplatin in Biliary Tract Malignancies
Evaluating the efficacy and safety of adebrelimab in combination with apatinib, gemcitabine and cisplatin in the neoadjuvant treatment of patients with biliary tract malignancies.
- Trial name
- NCT06181032
- Testing
- Adebrelimab, Apatinib, Gemcitabine
- Where
- China
- Volunteers
- 35 people
- Sponsor
- First Affiliated Hospital of Fujian Medical University
BCLC Stage C Hepatocellular Carcinoma, Chemotherapy Effect
Infusional FOLFOX Plus Camrelizumab and Apatinib vs HAIC-FOLFOX Plus Camrelizumab and Apatinib for Advanced HCC
This is a multi-center randomized phase III clinical study of first-line intravenous FOLFOX plus Camrelizumab and apatinib versus HAIC-FOLFOX plus Camrelizumab and apatinib for BCLC C stage hepatocellular carcinoma.
- Trial name
- NCT06172205
- Testing
- intravenous FOLFOX7 plus Camrelizumab and apatinib, HAIC-FOLFOX plus Camrelizumab and apatinib
- Where
- China
- Volunteers
- 262 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Sarcoma
A Study of Carilizumab in Combination With Apatinib in Subjects With Unresectable UPS and ASPS
This study is a Single-arm, Open, Prospective, Single-center, Phase Ⅱ Clinical Study ,Target population is Advanced Inoperable Resection of Undifferentiated Pleomorphic Sarcoma (UPS) and Alveolar Soft Tissue Sarcoma (ASPS) .
- Trial name
- NCT04447274
- Testing
- Camrelizumab and Apatinib
- Volunteers
- 20 people
- Sponsor
- Chinese Academy of Medical Sciences
Advanced Breast Cancer, HR+/HER2- Breast Cancer
Apatinib Combined With cdk4/6i in First-line Treatment for HR+/HER2- SNF4 Subtype Breast Cancer
This is a randomized, controlled, open-label, phase III study to explore the efficacy and safety of Apatinib in combination with standard first-line endocrine therapy for the HR+/ HER2-SNF4 subtype of advanced breast cancer.
- Trial name
- NCT06447623
- Testing
- Apatinib, CDK4/6 Inhibitor, Aromatase inhibitor and Fulvestrant
- Where
- China
- Volunteers
- 184 people
- Sponsor
- Fudan University
Carcinoma, Non-Small-Cell Lung
A Study of SHR-1210 in Combination With Apatinib in Advanced Non-Small Cell Lung Cancer(NSCLC)
This is a multi-center, open-label, Phase II study of intravenous (IV) SHR-1210 at 200mg, q2w in combination with Apatinib at two dose levels in subjects with locally advanced or metastatic non-small cell lung cancer (NSCLC).
- Trial name
- NCT03083041
- Testing
- SHR-1210, Apatinib
- Where
- China
- Volunteers
- 210 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Melanoma
PD-1 Antibody SHR-1210 Combined With Apatinib of First-line Treatment of Advanced Acral Melanoma
the investigators launched this exploratory study to evaluate the objective response rate (ORR) of SHR-1210 combined with apatinib mesylate in the first-line treatment of patients with advanced acral melanoma.
- Trial name
- NCT03955354
- Testing
- SHR1210, apatinib mesylate
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Peking University Cancer Hospital & Institute
Limited-stage Small Cell Lung Cancer (LS-SCLC)
Adjuvant Adebrelimab Plus Apatinib After Chemoradiation in Limited-Stage Small Cell Lung Cancer
The study includes the screening period (from the time the subject signs the informed consent form to no more than 28 days before the first dose, imaging evaluations are allowed within 28 days before the first dose, and 5-14 days…
- Trial name
- NCT06773156
- Testing
- Adebrelimab + Apatinib
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Second Affiliated Hospital of Nanchang University
Metastatic Castration Resistant Prostate Cancer
A Trial of SHR3162 Combined With Apatinib Mesylate Tablets or SHR3162 Monotherapy in Patients With Metastatic Castration Resistant Prostate Cancer
Main research purpose: To evaluate the effectiveness of Fluzoparib combined with apatinib mesylate in the treatment of patients with metastatic castration-resistant prostate cancer.
- Trial name
- NCT04869488
- Testing
- Fluzoparib, Enzalutamide OR abiraterone acetate With Prednisone Acetate Tablets, Fluzoparib Combined With Apatinib
- Where
- China
- Volunteers
- 93 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Advanced Malignancies, Urothelial Carcinoma
Apatinib With Pembrolizumab in Previously Treated Advanced Malignancies
This is an open label nonrandomized Phase I/ IIA trial designed to assess the safety, tolerability, and efficacy of apatinib in combination with pembrolizumab.
- Conditions
- Advanced Malignancies, Urothelial Carcinoma, MSI-H or dMMR Solid Tumors, Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
- Trial name
- APPEASE (NCT03407976)
- Testing
- Apatinib, Pembrolizumab
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Utah
Advanced Hepatocellular Carcinoma
Adebrelimab, Camrelizumab Plus Apatinib as First-line Therapy in Patients With Advanced Hepatocellular Carcinoma
This is a prospective, single-arm, phase Ib/II trial . The objective of this study is to evaluate the efficacy and safety of adebrelimab, camrelizumab plus apatinib as first-line therapy in patients with advanced hepatocellular…
- Trial name
- NCT05924997
- Testing
- adebrelimab, camrelizumab plus apatinib
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University